NASDAQ: INVAInnoviva Inc Stock
$14.99-0.17 (-1.12%)
Updated Apr 25, 2024
INVA Price
$14.99
Fair Value Price
$17.80
Market Cap
$947.78M
52 Week Low
$11.37
52 Week High
$16.87
P/E
5.45x
P/B
1.4x
P/S
3.38x
PEG
N/A
Dividend Yield
N/A
Revenue
$310.46M
Earnings
$179.72M
Gross Margin
86.3%
Operating Margin
68.69%
Profit Margin
57.9%
Debt to Equity
0.84
Operating Cash Flow
$141M
Beta
0.8
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
INVA Overview
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INVA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INVA ($14.99) is undervalued by 15.8% relative to our estimate of its Fair Value price of $17.80 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
INVA ($14.99) is not significantly undervalued (15.8%) relative to our estimate of its Fair Value price of $17.80 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INVA was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more INVA due diligence checks available for Premium users.
Be the first to know about important INVA news, forecast changes, insider trades & much more!
INVA News
Valuation
INVA fair value
Fair Value of INVA stock based on Discounted Cash Flow (DCF)
Price
$14.99
Fair Value
$17.80
Undervalued by
15.80%
INVA ($14.99) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INVA ($14.99) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INVA was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
5.45x
Industry
15.41x
Market
40.97x
INVA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INVA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
INVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.4x
Industry
5.8x
INVA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INVA's financial health
Profit margin
Revenue
$85.8M
Net Income
$61.5M
Profit Margin
71.7%
INVA's Earnings (EBIT) of $213.26M... subscribe to Premium to read more.
Interest Coverage Financials
INVA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$568.6M
Debt to equity
0.84
INVA's short-term assets ($344.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INVA's long-term liabilities ($530.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INVA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$33.3M
Investing
-$5.2M
Financing
-$14.6M
INVA's operating cash flow ($141.06M)... subscribe to Premium to read more.
Debt Coverage Financials
INVA vs Biotech Stocks
Innoviva Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.